Bad Blood: CSL Will Challenge FTC Lawsuit Over Its Acquisition of Talecris

Expressing frustration with regulators, CSL will challenge a Federal Trade Commission lawsuit being filed to block its planned $3.1 billion acquisition of Talecris Biotherapeutics, company executives said May 28